Genetics Generation Advancement Corp. (4160) AI Stock Analysis

Genetics Generation Advancement Corp.

(TPEx:4160)

Select Model

Rating:45Neutral

Price Target:TWD 33.00▼(-7.17% Downside)

Action:initiatedcoverage

Date:11/10/26

The overall score of 45 is significantly low, reflecting a high-risk profile. The most critical factor is the company's severe cash flow deterioration, where core operations are burning cash despite reported revenue growth. This is compounded by a strongly bearish technical trend with the stock in oversold territory. While the balance sheet is stable with low debt and the dividend yield is attractive, these are insufficient to offset the fundamental operational and market momentum risks.

Positive Factors

Healthy Balance SheetRelatively low leverage and an accumulated equity base provide financial resilience and reduce solvency pressure. This gives the company more flexibility to absorb weaker profitability, maintain operations, and fund selected investments without relying heavily on additional borrowing.

Negative Factors

Negative Cash GenerationThe sharp reversal from consistently positive operating and free cash flow raises concern that reported earnings are not currently translating into usable cash. Persistent weakness could increase funding needs, limit reinvestment capacity, and make results more volatile over the next several quarters.

Genetics Generation Advancement Corp. (4160) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 995.89M
Dividend Yield: 4.93%
Average Volume (3M): 32.59K
Price to Earnings (P/E): 52.6
Beta (1Y): 0.49
Revenue Growth: 0.10%
EPS Growth: -44.49%
Country: TW
Employees: 169
Sector: General
Sector Strength: 55
Industry: Medical - Diagnostics & Research

Genetics Generation Advancement Corp. Business Overview & Revenue Model

Company Description

Genetics Generation Advancement Corp. (GGAC), headquartered in Taipei, Taiwan, specializes in providing advanced genetic testing and bioinformatics solutions. The company serves a diverse global clientele across Taiwan, Asia, Europe, and the Americas...

Genetics Generation Advancement Corp. Financial Statement Overview

Summary

Financial performance is weak, driven by a severe cash flow crisis (Score: 15) and deteriorating profitability (Income Score: 45), despite a healthy balance sheet (Score: 78). The inability to convert revenue growth into operating cash flow is a critical red flag.

Income Statement

45Neutral

Balance Sheet

78Positive

Cash Flow

15Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	614.42M	603.11M	661.86M	592.50M	547.81M	519.51M
Gross Profit	253.79M	250.44M	280.01M	236.83M	226.44M	195.49M
EBITDA	29.61M	37.22M	85.95M	50.60M	44.01M	20.48M
Net Income	17.98M	21.46M	54.70M	28.57M	25.73M	7.84M
Balance Sheet
Total Assets	717.86M	806.05M	724.30M	595.05M	455.66M	424.76M
Cash, Cash Equivalents and Short-Term Investments	320.81M	408.95M	414.48M	315.61M	259.24M	200.57M
Total Debt	126.53M	80.08M	41.19M	49.30M	3.33M	2.42M
Total Liabilities	224.20M	204.05M	170.81M	164.91M	108.20M	106.06M
Stockholders Equity	493.08M	601.55M	553.13M	429.94M	347.46M	318.92M
Cash Flow
Free Cash Flow	-35.90M	-49.64M	55.61M	61.74M	43.67M	-3.11M
Operating Cash Flow	-140.00K	-18.33M	81.62M	66.86M	51.81M	7.32M
Investing Cash Flow	-40.90M	-26.34M	-60.42M	-7.80M	-71.52M	10.19M
Financing Cash Flow	40.44M	-18.51M	-20.96M	12.25M	-7.80M	-751.00K

Genetics Generation Advancement Corp. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4160 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4160	45Neutral	TWD 1.00B	52.56	―	4.93%	0.10%	-44.49%
TW:4171	40Underperform	TWD 896.99M	-40.49	―	―	11.99%	84.94%

* General Sector Average

Performance Comparison

TW:4160 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4160	Genetics Generation Advancement Corp.	35.55	-16.18	-31.28%
TW:4171	GeneReach Biotechnology Corp.	15.20	-4.85	-24.19%
TW:6539	DV Biomed Co., Ltd.	36.20	-17.15	-32.15%
TW:6810	Bio Preventive Medicine Corp.	22.70	-1.40	-5.81%
TW:6879	Tci Gene Inc.	35.50	-3.65	-9.32%
TW:7725	LabTurbo Biotech Corporation	20.85	-1.96	-8.59%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Genetics Generation Advancement Corp. AI Stock Analysis